MediciNova Initiates Phase II Trial on Insomnia Pill
Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics on January 25, 2007
Biopharmaceutical company MediciNova, Inc. announced the initiation of a Phase II clinical study to determine the safety and efficacy of MN-305 for the treatment of insomnia.
MN-305 is a potent and highly-selective full agonist at the serotonin 5-HT1A receptor under development both for the treatment of insomnia as well as for anxiety disorders such as generalized anxiety disorder (GAD). MN-305 has been evaluated in an extensive preclinical toxicology program which showed no evidence of mutagenicity, antigenicity or carcinogenicity. MN-305 has also proved to be consistently well-tolerated in clinical safety, efficacy and pharmacokinetic studies in over 1,200 subjects.
MediciNova acquired a license to MN-305 from Mitsubishi Pharma Corporation for global markets, with the exception of Japan and other selected Asian countries.
Source: MediciNova
Tags: insomnia sleep sleeping+disorders MediciNova biotech phase+trial insomnia+pill trial+insomnia
Vote for MediciNova Initiates Phase II Trial on Insomnia Pill:
|
Rating: 7.00 out of 2 vote(s) cast.
|
| RSS |  |
 | |
| Yahoo! |
|
| Addthis |
|
| Bloglines |
|
Most Popular
Best of
Biotech Hubs and Facilities
Biotech/Science Blogs
Corporate and Industrial News
Diagnostics, Methodologies and Instrumentation
Did you know
Drugs, Vaccines and Therapeutics
Energy, Environment and Ecology
Food and Agriculture
Gene Therapy
Genomics, Proteomics and Bioinformatics
Information About
Meetings and Other Events
Microbiology
Misc
Nanomedicine
Other Biotechnology News
Patents and Intellectual Property Rights
Quick introduction
Stem Cells